ENIS IIIEfficacy and safety of Nelonemdaz (Neu2000) in acute Ischemic Stroke patients (PIII)

• A Phase III clinical trial in China to verify safety and efficacy of nelonemdaz in 948 patients with moderate and severe acute stroke receiving thrombolytics within 8 hours after stroke onset.
• Participating Hospitals (Department of Neurology): 39 university hospitals, including Tiantan Hospital, Capital Medical University in Beijing.
• This trial commenced in September 2020 (first patient enrolled on December 25, 2020).
• IDMC Review (Sep 2022), “Continue as planned.”
• Due to long-lasting COVID-19 pandemic in China, ENIS-3 was terminated early in January 2024.